scholarly journals An investigation of the efficacy on hepatitis B vaccination in hemodialysis patients in Ardabil, Iran

2018 ◽  
Vol 8 (1) ◽  
pp. 6-10
Author(s):  
Susan Mohammadi Kebar ◽  
Saeed Hoseininia ◽  
Yousef Mohammadi Kebar ◽  
Mohammad Broumand
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Poor Response ◽  
Hemodialysis Patients ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Double Dose ◽  
Serological Markers ◽  
The Past ◽  
Lower Immune Response

Introduction: Hemodialysis patients usually demonstrate lower immune response to hepatitis B vaccine compared to non-uremic population. Objectives: The present study aimed to determine the level of response to hepatitis B vaccination in patients under hemodialysis. Patients and Methods: This study was conducted on 172 live patients receiving hemodialysis in the dialysis department of Buali hospital in Ardabil, Iran (2015). To analyze their response to the vaccine, their vaccination titers were investigated. Before vaccination, the serological markers of hepatitis B and C were checked in all of the patients. Those for whom HBsAg and HBsAb results were negative and had not received the vaccinein the past entered the study. The patients received a double dose of hepatitis B vaccine at 0, 1, and 6 months after the beginning of dialysis. The response to the vaccine was investigated by measuring the level of patients’ hepatitis B antibody one month after receiving the last dose of the vaccine. Results: Seventy patients (40% of the total) displayed a proper immune response to the vaccine, 34 patients (19.8%) were without, and 68 patients (39.5%) were identified to have poor response. The results of Pearson’s correlation test indicated that there is a negative correlation between the patients’ age and their response to the vaccine. Conclusion: The results of this study indicated that higher age is one of the factors that reduce the effectiveness of hepatitis B vaccine in hemodialysis patients.

Effect of Oral Levamisole Supplementation to Hepatitis B Vaccination on the Rate of Immune Response in Chronic Hemodialysis Patients

Nephron ◽  
2000 ◽  
Vol 84 (3) ◽  
pp. 291-292 ◽  
Author(s):  
M. Deniz Ayli ◽  
Cüneyt Ensari ◽  
Meltem Ayli ◽  
Fahri Mandiroglu ◽  
Suat Mut
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Hepatitis B Vaccination

scholarly journals Antibody response to heat-inactivated hepatitis B vaccine (CLB-3mg) in hemodialysis patients and occupational risk personnel: a one year follow-up

1988 ◽  
Vol 30 (1) ◽  
pp. 11-16
Author(s):  
C. F. T. Yoshida ◽  
C. Takahashi ◽  
L. A. C. Mercadante ◽  
I. F. Camargo ◽  
H. G. Schatzmayr
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Hepatitis B Vaccine ◽  
Occupational Risk ◽  
Immunization Schedule ◽  
One Year ◽  
Sample Ratio ◽  
Healthy Persons

Immune response against hepatitis B vaccine (CLB 3mg) was evaluated in 59 hemodialysis patients and 20 occupational risk personnel. Seroconversion was induced in 52.5% and 70.0% respectively. Twelve months after the first dose, 37.5% of patients and 60.0% of occupational risk personnel had detectable anti-HBs level. Antibody level was expressed in sample ratio units (SRU). Considering only the responders, in the patients group 38.7% had a low anti-HBs response (2.1-9.9 SRU) 32.3% a medium response (10-99.9 SRU) and 29.0% a high response (>100 SRU) while in occupational risk personnel these values were 14.3%, 64.3% and 21.4% respectively. The authors suggest the use of HBV vaccines with more elevated HBsAg concentration or a reinforced immunization schedule to improve the anti-HBs response not only for patients but also for healthy persons.

Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients

Vaccine ◽  
2020 ◽  
Vol 38 (24) ◽  
pp. 3995-4000 ◽  
Author(s):  
Jung-Hwan Lee ◽  
Seri Hong ◽  
Jae Hyoung Im ◽  
Jin-Soo Lee ◽  
Ji Hyeon Baek ◽  
...  
Keyword(s):  
Systematic Review ◽  
Immune Response ◽  
Hepatitis B ◽  
Meta Analysis ◽  
Hepatitis B Vaccination ◽  
Double Dose

Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination

Vaccine ◽  
2011 ◽  
Vol 29 (12) ◽  
pp. 2242-2247 ◽  
Author(s):  
Theodoros Eleftheriadis ◽  
Vassilios Liakopoulos ◽  
Georgia Antoniadi ◽  
Ioannis Stefanidis ◽  
Grammati Galaktidou
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Hepatitis B Vaccination ◽  
Indoleamine 2,3 Dioxygenase

scholarly journals A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients

2008 ◽  
Vol 73 (7) ◽  
pp. 856-862 ◽  
Author(s):  
N.C.T. Kong ◽  
J. Beran ◽  
S.A. Kee ◽  
J.L. Miguel ◽  
C. Sánchez ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Hepatitis B Vaccine

scholarly journals Immune response to hepatitis B vaccine following complete immunization of children attending two regional hospitals in the Southwest region of Cameroon: a cross sectional study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ephesians N. Anutebeh ◽  
Lambed Tatah ◽  
Vitalis F. Feteh ◽  
Desmond Aroke ◽  
Jules C. N. Assob ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Large Scale ◽  
Public Health Problem ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Cross Sectional ◽  
Factors Associated ◽  
Regional Hospitals ◽  
Surface Antibody

Abstract Background Hepatitis B virus (HBV) infection despite being a vaccine preventable disease remains a global public health problem. In Cameroon, the hepatitis B vaccine was introduced in the expanded program on immunisation in 2005, but there has been limited evaluation of the HBV surface antibody response post vaccination. Objective We investigated the immune response to hepatitis B vaccine in infants who received the DPT-Hep B-Hib vaccine, and we assessed HBsAg carriage in non-responders. We also investigated factors associated with non-response or poor response. Methods Using a hospital based cross sectional design and a structured questionnaire over a four-month period (January to April 2019), we collected data to determine factors associated with hepatitis B surface antibody (anti-HBs) response from infants aged 6 to 9 months attending infant welfare clinics (IWC) at the Buea and Limbe regional hospitals. We collected venous blood and measured anti-HBs titres using a quantitative Foresight® ELISA. We entered and analysed data using EpiData version 3.1 and SPSS version 25 respectively. Results Of the 161 infants enrolled, 159 (98.8%) developed anti-HBs antibodies. Of these 159, 157 (97.5%) and 117 (72.7%) developed ≥ 10.0 mIU/ml (seroprotection) and ≥ 100.0 mIU/ml anti-HBs titres respectively. Being younger (6 months old) was associated with seroprotection (Cramer V = 0.322, p = 0.001). Spearman rho’s relational analysis showed that immunity against HBV reduced as the duration since the last dose increased (r = −0.172; P = 0.029). However, a Firth logistic regression showed no significant association of factors with inadequate immunity. All 12 (7.5%) infants exposed to HBV at birth, received the hepatitis B vaccine at birth, including four who received HBIG, and all were protected. Four infants (2.5%) had anti-HBs titres < 10.0 mIU/mL (non-responders) but had no peculiarity. Conclusion The seroprotective rate following hepatitis B vaccination of infants is high even in exposed infants. Our study suggests that Cameroon’s HBV vaccine in the Expanded Program on Immunisation (EPI) is effective against HBV, although we could not account for the 2.5% non-response rate. Large scale studies are needed to further explore non-response to the vaccine.

scholarly journals The significance of age and sex for the absence of immune response to hepatitis B vaccination

2008 ◽  
Vol 136 (1-2) ◽  
pp. 33-37 ◽  
Author(s):  
Ilija Rosic ◽  
Sead Malicevic ◽  
Snezana Medic
Keyword(s):  
Immune Response ◽  
Relative Risk ◽  
Hepatitis B ◽  
Population Sample ◽  
Age Groups ◽  
Deltoid Muscle ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Vaccine Manufacturer ◽  
Significant Difference

INTRODUCTION Seroepidemiological investigations after the administration of hepatitis B vaccine have shown that even 15% of vaccinated healthy persons do not generate immune response to the vaccines currently in use. OBJECTIVE The aim of the research is to test the immunogenicity of hepatitis B vaccine in different age groups on the adult vaccinated population sample in Serbia. METHOD The tested general population sample consisted of 154 adult subjects. Immunization was done using the recombinant fungal vaccine obtained by genetic engineering (Euvax B vaccine, manufacturer LG, distributor Sanofi Pasteur). All tested subjects in the research received 1 ml of hepatitis B vaccine administered intramuscularly into the deltoid muscle by 0, 1, 6 schedule. RESULTS In the tested sample, 3.13% of persons aged up to 29 years, 6.25% aged 30-35 year and 19.23% of the tested persons aged 40 years and older had no immune response. The relative risk of ?no response" findings was twice higher in the group aged 30-39 as compared to the population aged up to 29 years. The detected risk was six times higher for the population of 40 years and older in comparison to the population aged up to 29 years. Also, the relative risk of ?no response" findings for the population of 40 years and older was more than three times higher than for the group aged 30-39. Absent immune response in relation to sex was found to be higher in male subjects. CONCLUSION The rates of ?no response" finding was the following: 3.13% in the group aged up to 29 years, 6.25% in the group aged 30-39, as well as in the group aged 40 years and older (19.23%). Immune response in relation to age groups was statistically significantly different (p<0.001), while there was a statistically significant correlation (C=0.473; p<0.001) between the age of the subjects and the immune response. In relation to sex, the ?no response" finding was found to be increased in the males, but without any statistically significant difference (p>0.05).

Immune Response to a Recombinant Hepatitis B Vaccine in Hemodialysis Patients

1990 ◽  
Vol 13 (7) ◽  
pp. 451-453 ◽  
Author(s):  
D. Docci ◽  
P.A. Cipolloni ◽  
L. Baldrati ◽  
C. Capponcini ◽  
F. Turci ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Hepatitis B Vaccine ◽  
Recombinant Hepatitis
Sign in / Sign up

Export Citation Format

Share Document